Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Objective To update evidence‐based medicine recommendations for treating nonmotor
symptoms in Parkinson's disease (PD). Background The International Parkinson and Movement …

The clinical diagnosis of Parkinson's disease rests on the identification of the characteristics
related to dopamine deficiency that are a consequence of degeneration of the substantia …

Several studies, including work from the Parkinson's disease (PD) non-motor group and
others, have established that the non-motor symptoms of PD are common, occur across all …

Many of the motor symptoms of Parkinson disease (PD) can be preceded, sometimes for
several years, by non-motor symptoms that include hyposmia, sleep disorders, depression and …

The accuracy of the clinical diagnosis of corticobasal degeneration (CBD) is unknown.To
determine its diagnostic accuracy, we presented 105 cases with known neuropathologic …

Background: Non‐motor symptoms are detrimental to health‐related quality of life (HRQoL)
of Parkinson's disease patients. In this study, the Non‐Motor Symptoms Scale (NMSS) was …

Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment …

2006, there was, no single instrument (questionnaire or scale) for attempting a comprehensive
assessment of the wide range of nonmotor symptoms (NMS) of Parkinson's disease (PD). …

… Financial Disclosures: K. Ray Chaudhuri has received funding as advisor and speaker in
sponsored symposiums from Boehringer-Ingelheim, Solvay, UCB pharma, Brittannia …